Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Means ratings for FFM traits at each age interval for the self and others with post hoc analyses for mean differences. by Joanna Gutral (12101779)

Distribution of mean seasonal rainfall in the study area. by Menbere Sahilu (18195856)

Subjects:

Distribution of mean monthly rainfall in the study area. by Menbere Sahilu (18195856)

Subjects:

Percentage decrease in model output peak with the administration of exogenous estrogen/progesterone. by Brenda Lyn A. Gavina (15285185)

Descriptive statistics of data presented in Tables 2–5. by Héctor Raúl Olivares-Sánchez (13014866)

RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression. by Xiaojuan Li (351842)

Chemokines, with the exception of CXCL1 and MCP-1, decrease acutely following 5 Gy IR. by Jordan A. Gunning (18143970)

Fig 5 - by Harshita Sharma (4836180)

Descriptive statistics (mean [standard deviation] or % [sample size]) for study variables analyzed in the current study. by Angelina R. Sutin (9216456)

Mean change in pain severity and interference from baseline to 8 weeks. by Judith I. Tsui (5983160)

Subjects: